论文部分内容阅读
四价脑膜炎球菌多糖-CRM197蛋白结合疫苗对婴幼儿有免疫效果。我们评估了婴幼儿初免和加强免疫该疫苗后的记忆性B淋巴细胞应答和抗体应答水平。5个月龄的婴幼儿初免疫苗后,有25%的婴幼儿体内可以检测到血清特异性记忆性B淋巴细胞,69%的婴幼儿体内可检测到针对A群脑膜炎球菌的保护性抗体滴度(hSBA≥4),超过95%的婴幼儿体内可以检测到针对其他群脑膜炎球菌的保护性抗体滴度。12个月龄的婴幼儿在进行加强免疫前,针对A群脑膜炎球菌的保护性抗体滴度
Quadrivalent meningococcal polysaccharide-CRM197 protein conjugate vaccine has an immunogenic effect on infants and young children. We evaluated memory B lymphocyte responses and antibody response levels after infant immunization and boosting of the vaccine. Serum-specific memory B lymphocytes can be detected in 25% of infants and young children after 5 months of age, and 69% of infants and young children can detect protective antibodies to meningococcal group A Titers (hSBA> 4), protective antibody titers against other groups of meningococci can be detected in more than 95% of infants. Protective antibody titers against group A meningococci before 12-month-old infants were boosted